The New England Journal of Medicine DECEMBER 08, 2011

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection (PREVENT TB)

Sterling TR, Villarino ME, Borisov AS, et al. (Tuberculosis Trials Consortium)

Bottom Line

The PREVENT TB trial demonstrated that a three-month, once-weekly regimen of isoniazid and rifapentine (3HP) is non-inferior to the standard nine-month regimen of daily isoniazid (9H) for preventing active tuberculosis in high-risk individuals.

Key Findings

1. The 3HP regimen was found to be non-inferior to the 9H regimen for the prevention of active tuberculosis disease, with an incidence of 0.19% in the 3HP arm compared to 0.43% in the 9H arm.

2. Treatment completion rates were significantly higher in the 3HP arm (82.1%) compared to the 9H arm (69.0%), demonstrating the superior adherence potential of the shorter, directly-observed regimen.

3. While 3HP was associated with higher rates of systemic drug reactions compared to 9H, the incidence of severe adverse events and hepatotoxicity remained low, establishing the regimen's favorable safety profile.

4. The findings hold across various subpopulations, including those with HIV infection, supporting the use of 3HP as a robust alternative to prolonged isoniazid monotherapy.

Study Design

Design

RCT

Open-Label

Sample

7,731

Patients

Duration

33 mo

Median

Setting

Multicenter, International

Population Individuals aged 12 years or older at high risk for tuberculosis infection (household contacts, recent tuberculin skin-test converters, or persons with fibrotic lesions on chest radiography, including those with HIV)

Intervention Once-weekly isoniazid (15 mg/kg) plus rifapentine (900 mg) for 12 weeks administered via directly observed therapy

Comparator Nine months of daily self-administered isoniazid (300 mg)

Outcome Development of active tuberculosis disease

Study Limitations

• The study required directly observed therapy for the 3HP arm, which may limit scalability in resource-constrained settings compared to self-administered regimens.

• Systemic drug reactions, though typically self-limiting, occurred more frequently with 3HP, potentially impacting patient tolerance in real-world clinical practice.

• The trial was open-label, which could introduce bias in the reporting of subjective adverse events or adherence assessments.

• The study primarily evaluated efficacy in high-risk populations, and findings may need careful extrapolation to lower-risk, general populations.

Clinical Significance

This landmark study shifted the paradigm of latent tuberculosis infection treatment by validating a significantly shorter, better-tolerated, and highly effective regimen (3HP), facilitating higher completion rates and contributing to global TB elimination targets.

Historical Context

Prior to this trial, the standard of care for latent tuberculosis was 6 to 9 months of daily isoniazid, a regimen notoriously plagued by poor patient adherence, long treatment duration, and risks of hepatotoxicity. The PREVENT TB trial provided the definitive Phase III evidence required to endorse shorter, rifamycin-based, once-weekly regimens as the preferred standard of care in international guidelines.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What are the distinct mechanisms of action for isoniazid and rifapentine, and why does the pharmacokinetics of rifapentine specifically allow for once-weekly dosing compared to traditional rifampin?

Key Response

Isoniazid inhibits mycolic acid synthesis, essential for the mycobacterial cell wall. Rifapentine, like rifampin, inhibits DNA-dependent RNA polymerase. The 'high-yield' point for students is that rifapentine has a significantly longer half-life (approx. 13-15 hours) than rifampin (approx. 2-3 hours), enabling a high-peak concentration that maintains inhibitory levels over a week, facilitating the transition from daily to weekly dosing in latent TB therapy.

Resident

A patient with latent TB infection (LTBI) is starting the 3HP regimen. Beyond hepatotoxicity, what specific adverse reaction unique to the weekly rifapentine/isoniazid combination should the resident monitor for, and how does the treatment completion rate compare to the 9H regimen?

Key Response

Residents must recognize the 'flu-like' systemic hypersensitivity reaction associated with high-dose weekly rifapentine, which can include fever, chills, and hypotension. Clinically, the PREVENT TB trial found 3HP had significantly higher treatment completion rates (82.1% vs. 69.0%) compared to 9 months of isoniazid, making it a preferred option for improving population-level adherence.

Fellow

In the context of the PREVENT TB trial and subsequent updates, what are the critical pharmacokinetic considerations when prescribing 3HP to HIV-positive patients on Antiretroviral Therapy (ART)?

Key Response

Rifapentine is a potent inducer of the Cytochrome P450 system (specifically CYP3A4). While the trial included HIV-infected individuals, fellows must manage the drug-drug interactions: 3HP is generally compatible with Efavirenz or Raltegravir-based regimens but was historically contraindicated with Protease Inhibitors (PIs) and certain integrase inhibitors due to significant reductions in ART drug levels, necessitating careful regimen coordination.

Attending

The PREVENT TB trial utilized Directly Observed Therapy (DOT) for the 3HP arm. How should the subsequent evidence regarding Self-Administered Therapy (SAT) for 3HP influence your decision to prescribe this regimen in a busy outpatient clinical setting?

Key Response

While PREVENT TB established non-inferiority under DOT, later trials (like iAdhere) demonstrated that SAT is also non-inferior to DOT for 3HP in the US. Attending-level insight involves balancing the logistical hurdles of DOT against the patient's social determinants of health; 3HP is now widely accepted as SAT, which drastically reduces the public health infrastructure burden compared to the 9H standard.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The PREVENT TB trial used a non-inferiority margin of 0.75%. Critique the selection of this margin in the context of TB's low event rate in latent populations and its impact on the required sample size and statistical power.

Key Response

In LTBI trials, event rates (progression to active TB) are very low. Choosing a narrow non-inferiority margin (0.75%) requires a massive sample size (n=nearly 8,000) to ensure the upper bound of the 95% CI for the rate difference does not exceed the margin. A researcher must evaluate if this margin is clinically meaningful or if it reflects a 'safety' buffer to ensure that even a slight loss in efficacy wouldn't result in an unacceptable public health risk.

Journal Editor

Given that the PREVENT TB trial was an open-label study, what measures were essential to mitigate detection bias regarding the primary endpoint of active tuberculosis, and how does the attrition rate across a 33-month follow-up affect your assessment of the study's rigor?

Key Response

As an editor, the concern is that providers might monitor the 3HP group more or less intensely. The study mitigated this through a blinded independent end-point review committee. Furthermore, the editor would flag the 'Loss to Follow-up' as a threat to validity; however, the trial's use of both modified intention-to-treat and per-protocol analyses to demonstrate consistent non-inferiority provides the necessary methodological robustness.

Guideline Committee

How did the results of the PREVENT TB trial shift the CDC/NTCA recommendations for LTBI treatment, and how does 3HP compare to the 4-month daily rifampin (4R) regimen in the current hierarchy of recommendations?

Key Response

The PREVENT TB trial was pivotal in moving 3HP from an 'alternative' to a 'preferred' regimen. Current CDC/NTCA guidelines (2020) now prioritize short-course rifamycin-based regimens (3HP, 4R, or 3HR) over 6 or 9 months of isoniazid. The committee classifies 3HP as a 'Strong Recommendation' with high certainty in evidence for adults and children over 2 years old, specifically noting that the shorter duration improves the likelihood of treatment completion.

Clinical Landscape

Noteworthy Related Trials

2018

The BEAT Tuberculosis Trial

n = 3,000 · NEJM

Tested

Short-course rifapentine and isoniazid weekly

Population

Patients with latent tuberculosis infection

Comparator

Standard daily isoniazid for 9 months

Endpoint

Incidence of active tuberculosis or death

Key result: Short-course rifapentine and isoniazid was noninferior to daily isoniazid for preventing active tuberculosis with higher completion rates.

2018

The ACTG A5279 Trial

n = 3,000 · NEJM

Tested

One month of daily rifapentine and isoniazid

Population

HIV-infected persons with latent tuberculosis infection

Comparator

Nine months of daily isoniazid

Endpoint

Incidence of tuberculosis or death

Key result: A one-month regimen of daily rifapentine and isoniazid was noninferior to nine months of isoniazid for preventing tuberculosis in people with HIV.

2019

The iAdhere Trial

n = 1,000 · JAMA

Tested

Weekly rifapentine and isoniazid self-administered

Population

Patients with latent tuberculosis infection

Comparator

Directly observed therapy

Endpoint

Treatment completion rate

Key result: Self-administered 3HP was noninferior to directly observed 3HP in treatment completion, demonstrating that supervision is not strictly required.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis